Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medical developments international limited - methoxyflurane, quantity: 999 mg/g - inhalation - excipient ingredients: butylated hydroxytoluene - indications as at 20 march 1998: self administration to conscious haemodynamically stable patients with trauma and associated pain, under supervision by personnel trained in its use (see dosage and administration). monitored conscious patients who require analgesia for the relief of pain in short surgical procedures such as the change of dressings (see dosage and administration).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 24.99 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: povidone; magnesium stearate; crospovidone; lactose monohydrate; microcrystalline cellulose; maize starch; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; sodium calcium edetate; trometamol; water for injections; sodium hydroxide - ultravist is indicated for all angiographic and urographic examinations and for contrast enhancement in computerised tomography.,ultravist 300 or 370 is indicated for use in contrast-enhanced mammography (cem) in adults, to visualise known or suspected lesions of the breast as an adjunct to mammography (with or without ultrasound).

Emirats Àrabs Units - anglès - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmalink store italy - 150 ml hdpe plastic bottle - solution - 160 mg/10 ml - ear nose , oropharynx-oral ulceration and inflammation

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - methylprednisolone, quantity: 4 mg - tablet - excipient ingredients: gelatin; maize starch; magnesium stearate; purified talc; lactose monohydrate - yonsa mpred is indicated for the treatment of patients with: newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or; patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or; patients with mcrpc who have received prior chemotherapy containing a taxane.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 30.7 mg - capsule, hard - excipient ingredients: gelatin; propylene glycol; dimethicone 12500; brilliant blue fcf aluminium lake; titanium dioxide; shellac; strong ammonia solution - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 24.6 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; hydroxypropylbetadex; purified water; flavour; sorbitol; methyl hydroxybenzoate; citric acid; sucrose; glycerol; monobasic sodium phosphate; potassium sorbate - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 24.6 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate; hydroxypropylbetadex; purified water; sucralose; sodium benzoate; citric acid; flavour - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 122.9 mg - capsule, hard - excipient ingredients: titanium dioxide; shellac; gelatin; dimethicone 12500; propylene glycol; brilliant blue fcf aluminium lake; strong ammonia solution - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - darolutamide, quantity: 300 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; calcium hydrogen phosphate; macrogol 3350; titanium dioxide; povidone - nubeqa is indicated for the treatment of patients with: ? non-metastatic castration resistant prostate cancer (nmcrpc) ? metastatic hormone-sensitive prostate cancer (mhspc) in combination with docetaxel